William Blair Reiterates “Outperform” Rating for Alto Neuroscience (NYSE:ANRO)

Alto Neuroscience (NYSE:ANRO)‘s stock had its “outperform” rating reaffirmed by equities research analysts at William Blair in a report issued on Friday,RTT News reports. William Blair also issued estimates for Alto Neuroscience’s Q1 2026 earnings at ($0.53) EPS, Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.43) EPS and Q4 2026 earnings at ($0.43) EPS.

Alto Neuroscience Stock Up 0.6 %

Shares of ANRO stock opened at $2.71 on Friday. The business’s 50 day simple moving average is $3.63 and its 200 day simple moving average is $6.10. Alto Neuroscience has a one year low of $2.58 and a one year high of $18.35. The company has a current ratio of 13.10, a quick ratio of 13.09 and a debt-to-equity ratio of 0.05.

Alto Neuroscience (NYSE:ANRO) last announced its earnings results on Thursday, March 20th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.09. As a group, equities analysts anticipate that Alto Neuroscience will post -2.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alto Neuroscience

Several institutional investors have recently added to or reduced their stakes in ANRO. Wells Fargo & Company MN lifted its stake in Alto Neuroscience by 40.0% in the fourth quarter. Wells Fargo & Company MN now owns 10,989 shares of the company’s stock valued at $46,000 after buying an additional 3,139 shares during the period. BNP Paribas Financial Markets lifted its stake in Alto Neuroscience by 619.2% in the third quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock valued at $49,000 after buying an additional 3,715 shares during the period. Deutsche Bank AG lifted its stake in Alto Neuroscience by 31.3% in the fourth quarter. Deutsche Bank AG now owns 15,210 shares of the company’s stock valued at $64,000 after buying an additional 3,629 shares during the period. Skandinaviska Enskilda Banken AB publ acquired a new position in Alto Neuroscience in the fourth quarter valued at approximately $74,000. Finally, Jane Street Group LLC lifted its stake in Alto Neuroscience by 72.0% in the fourth quarter. Jane Street Group LLC now owns 18,600 shares of the company’s stock valued at $79,000 after buying an additional 7,783 shares during the period.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.